Cyto-Cellect Fc Fusion Assay Kit launched to expedite cell line development for fusion proteins
Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
spherebio.comCrawled Oct 16, 2026
Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
The company launched the Cyto-Cellect Human IgG Kappa and Viability Assay Kit, a multiplexed assay developed for Cyto-Mine Chroma.
Sphere Bio Announces Cyto-Mine Chroma: the next generation of the single-cell analysis platform with multiplexed assays.
The company offers picodroplet products, including high-throughput platforms and consumables for single-cell analysis.
Sphere Bio's support team provides installation, hands-on training, ongoing assay development, and platform optimization.
The company offers picodroplet technology solutions for R&D.
The event on 21February 2024 at 1:30PM discusses how picodroplet technology can enable high-throughput single-cell screening and isolation.
The page describes producing highly productive, scalable, clonal cell lines for developing biopharmaceuticals.
Denise's more than 25 years of experience has shaped her career and the company's culture.
The page features a Q&A with Elena Shvets, the Group Leader of Application Development, about her role and career journey.
The company offers consumables for purchase and provides quotes through a form.
The company offers the Cyto-Cellect Probes Assay Kit (Cyto-Cellect Human IgGκ Detection Kit) and provides quotes through a form.
The company offers Cyto-Surf B for purchase and provides quotes through a form.
The company offers Pico-Surf (2% (w/w) in Novec 7500) and provides pricing and ordering information through a form.
The company offers Pico-Surf (5% (w/w) in Novec 7500) and provides pricing and ordering information through a form.
The company offers consumables for purchase and processes orders submitted through a form.
The page features Jonathan Dempsey's 2024 webinar, “Accelerating cell line development from transfection to manufacturing.”
The company lists events and conferences it attends and describes the use of picodroplet technology in primary research.
Sphere Bio describes a culture of innovation, collaboration, and care intended to support a motivated, global team.
Sphere Bio's global expansion led by new CEO, Dale Levitzke, addresses global demand for the Cyto-Mine Chroma platform.
Sphere Bio finds, analyzes, and isolates cells.

Sphere Bio builds Cyto-Mine picodroplet platforms for single-cell screening, sorting, and dispensing in antibody and cell-line discovery.